Reply to 'Therapeutic drug monitoring for isoniazid and rifampicin exposure'

O W Akkerman*, H A M Kerstjens, M Kingma, M S Bolhuis, M G G Sturkenboom

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

2 Citations (Scopus)
58 Downloads (Pure)
Original languageEnglish
Pages (from-to)169-170
Number of pages2
JournalThe International Journal of Tuberculosis and Lung Disease
Volume28
Issue number3
DOIs
Publication statusPublished - 1-Mar-2024

Keywords

  • Humans
  • Isoniazid/adverse effects
  • Rifampin/adverse effects
  • Drug Monitoring
  • Antitubercular Agents/adverse effects
  • Mycobacterium tuberculosis

Cite this